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Background
Deliberative forums can be useful tools in policy decision making for balancing citizen voice and
community values against dominant interests.

Objective
To describe the use of a deliberative forum to explore community perspectives on a complex health
problem—disinvestment.

Methods
A deliberative forum of citizens was convened in Adelaide, South Australia, to develop criteria to support
disinvestment from public funding of ineffective pathology tests. The case study of potential
disinvestment from vitamin B12/folate pathology testing was used to shape the debate. The forum was
informed by a systematic review of B12/folate pathology test effectiveness and expert testimony.

Results
The citizens identified seven criteria: cost of the test, potential impact on individual health/capacity to
benefit, potential cost to society, public good, alternatives to testing, severity of the condition, and
accuracy of the test. The participants not only saw these criteria as an interdependent network but also
questioned “the authority” of policymakers to make these decisions.

Conclusions
Coherence between the criteria devised by the forum and those described by an expert group was
considerable, the major differences being that the citizens did not consider equity issues and the experts
neglected the “cost” of social and emotional impact of disinvestment on users and the society.

Keywords
tests:, citizens', pathology, deliberative, publicly, forum, funded, disinvestment, perspectives

Disciplines
Education | Social and Behavioral Sciences

Publication Details
Street, J. M., Callaghan, P., Braunack-Mayer, A. J. & Hiller, J. E. (2015). Citizens' perspectives on
disinvestment from publicly funded pathology tests: a deliberative forum. Value in Health, 18 (8),
1050-1056.

This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/3785

Citizens’ perspectives on disinvestment from publicly funded
pathology tests: a deliberative forum
Jackie M. Street, PhD, BSc (Hons), Grad Dip PHC, School of Public Health, University of Adelaide
Peta Callaghan, PhD, BPysch, School of Public Health, University of Adelaide
Annette J. Braunack-Mayer, PhD, BMedSci (Hons) School of Public Health, University of Adelaide
Janet E. Hiller, PhD, MPH, BA, DipSocStudies, Swinburne University of Technology and School of
Public Health, University of Adelaide
Corresponding author: Jackie M. Street, School of Public Health, University of Adelaide, DX650 550,
Level 7, 178 North Tce, Adelaide, SA 5005. Email: jackie.street@adelaide.edu.au Tel: +61 883136498
Fax: +61 883136885
Financial support: This study was conducted as part of the ASTUTE Health Study (Assessing Services
and Technology Use To Enhance Health), a multidisciplinary research project funded by Australia’s
National Health and Medical Research Council (NHMRC, Grant ID 565327). Jackie Street is supported
by an NHMRC Capacity Building Grant (565501) and holds an Australian National Preventive Health
Agency Fellowship (20STR2013F).
Keywords: disinvestment; deliberative methods; pathology testing; evidence-based health policy
Running title: Citizens’ perspectives on disinvestment
Acknowledgements: Members of the ASTUTE Health Study Group who contributed to the study
reported here include Amber Watt, Michael Metz, Cameron Willis, Katherine Hodgetts, John Moss,
Dagmara Riitano and Adam Elshaug. We acknowledge their substantial contributions in supporting
the organisation and conduct of the deliberative forum.

Abstract

[First-level Header]

Objective: Deliberative forums can be useful tools in policy decision making for balancing citizen voice
and community values against dominant interests.
Methods: A deliberative forum of citizens was convened in Adelaide, South Australia to develop
criteria to support disinvestment from public funding of ineffective pathology tests. The case study of
potential disinvestment from Vitamin B12/folate pathology testing was used to shape debate. The
forum was informed by a systematic review of B12/folate pathology test effectiveness and expert
testimony.
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Findings: The citizens identified seven criteria: cost of the test, potential impact on individual
health/capacity to benefit, potential cost to society, public good, alternatives to testing, severity of the
condition and accuracy of the test. The participants saw these criteria as an interdependent network
but also questioned "the authority" of policy makers to make these decisions.
Conclusions: Coherence between the criteria devised by the forum and those described by an expert
group was considerable, the major differences being that the citizens did not consider equity issues
and the experts neglected the 'cost' of social and emotional impact of disinvestment on users and
society.
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Introduction

[First-level Header]

Increasing expectations from patients, in combination with highly-marketed expensive or high-volume
biomedical technologies, place pressure on health systems globally.(1) In this environment, decision
making can be found wanting if effectiveness, budget impact and safety are addressed with
inadequate attention to public acceptability and priorities.(2, 3) Public participation is increasingly
relevant in development of health policy, including the assessment of new and existing health
technologies, services and programs.(4-9)

Within health technology assessment, rigorous science-based knowledge is mostly undisputed and
seen as unbiased and objective (10-12) whereas experiential and values evidence provided by
patients and lay citizens tends to be seen as subjective and potentially biased. This ‘demarcationist
model’(13) presumes that lay citizens do not contribute relevant knowledge and experts and decisionmakers do not contribute values to decision making. Contemporary epistemological debates
challenge the demarcationist model, arguing that normative assumptions and science knowledge are
co-constituted, and that experts and non-experts alike reason using both knowledge and normative
assumptions.(10, 12, 13) Public deliberations, where participants consider the realities of health policy
development, can be conceptualised as collective processes of inquiry maximising mutual learning
and accountability within and across expert and non-expert groups.(13)

Deliberative forums provide unique opportunities for ‘ordinary’ citizens to engage in informed
deliberation, be exposed to the perspectives and experience of others and reach consensus on
recommendations for action.(1, 4, 8, 14-17) Public deliberations, employing disinterested non-expert
contributors, can make explicit non-technical barriers and facilitators to health care policy.(18) As
such, they balance the perspectives of dominant interests with those of less powerful citizen
stakeholders.(9, 13, 19)

This paper describes the use of a deliberative forum to explore community perspectives on a complex
health problem - disinvestment. ‘Disinvestment’ is “the process of (partially or completely) withdrawing
health resources from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for their cost, and thus are not
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efficient health resource allocations”.(20, p.2) More recently, disinvestment has been rebadged as
‘choosing wisely’ , ‘reappraisal’ or ‘reprioritisation’ in the lifecycle of technologies.(21) Disinvestment
evaluates existing health care services to redirect funding away from areas of potential inefficiency.(9)
As such, disinvestment presents scientific, political and ethical challenges: in particular, stakeholders
may be vested in current practice and such proposals may challenge long-held beliefs and put
livelihoods at risk.(22) Some pathology services exhibit characteristics, such as low test accuracy and
wide variability in test use, which suggest they may be candidates for disinvestment.(e.g. 23) In
particular, Vitamin B12 pathology testing has highly variable diagnostic accuracy and across
laboratory sites inconsistent cut-off values are used to define deficiency. In addition there are
geographical differences in test use, indications of usage outside guidelines and combined serum
B12/folate testing grew rapidly, with an annual growth rate in excess of 20% between 2000 and
2010.(23) Pathology testing, as a whole, grew in excess of any other medical activity within the
Australian health system.(24)

The deliberative forum reported in this paper aimed to incorporate community values in the
development of criteria to support potential disinvestment from public funding of ineffective pathology
tests. A case study of Vitamin B12/folate pathology testing was used to shape debate.

Methods

[First-level Header]

The research is part of the ASTUTE health study which, using HTA methods and deliberative
democracy, developed, trialled, and evaluated a model to integrate normative and scientific evidence
for disinvestment from health services with questionable safety, effectiveness and/or costeffectiveness profiles.(9) ASTUTE also conducted deliberative forums with primary care physicians,
pathologists(25) and federal government policy advisors. Findings from ASTUTE were fed back to
policy advisors.
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Deliberative process

[Second-level header]

The forum was held over a weekend in Adelaide, July 2011, during which a general medical
practitioner, epidemiologist, health economist and pathologist presented information and responded to
participants’ questions. The evidence provision reflected an evidence-based approach in keeping with
the format for the forums with clinicians and policy advisors.(9, 25) An independent facilitator was
engaged but withdrew due to ill-health. A research team member, with qualitative research expertise,
undertook the facilitation task. A court reporter provided immediate verbatim identified transcription of
forum proceedings. The forum participants were asked the following questions: (1) What things
should be considered when making decisions about how much we should publicly subsidise
B12/folate pathology tests? (2) Who should be involved in deciding which pathology tests are publicly
Commented [JMS1]: Reference needed to location of
supplementary material

subsidised? The forum schedule is provided on-line.

Recruitment of community forum participants [Second-level header]
Using stratified random sampling, jurors were recruited by an independent recruitment company from
a database drawn from a state-wide survey.(26) Sixteen participants were recruited to fulfil gender,
age and household income criteria but five withdrew prior to the forum. One female participant did not
return on day two, leaving 10 participants. An honorarium of $200 was provided.

Theoretical perspective and approach to analysis

[Second-level header]

Our analysis drew on realist approaches to discourse analysis particularly thematic analysis described
by Braun and Clarke.(27)Transcripts were coded independently by two authors (PC & JS), with
ongoing discussions throughout the analytic process.

Findings

[First-level Header]

The makeup of the forum mostly fulfilled the recruitment criteria: half were male, age ranged 20-66
years (median 41.5 - Australian median age is 36.9) and four participants had a weekly household
income less than $800 (median Australian household income).
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The citizens identified seven criteria, four primary and three secondary. (Table 1) In doing so, they
drew not only on the evidence provided in the forum but also on their experience and understandings
of medical care provision and community values.

Cost of test

[Second-level header]

Participants agreed that the cost of the test was a central point to consider for potential disinvestment,
although discussion focused on high item test cost or high overall budgetary impact rather than high
cost by volume per se.

P8: I don’t think anyone else is saying cost in and of itself would be one factor in isolation that we use,
you would weigh it up. [sentence omitted] With a finite amount of resources the cost of every
individual test surely is significant, surely has some bearing on your decision making about whether
you are going to fund or not.

Participants traded cost against potential outcomes, including accuracy of the test or as the following
extract demonstrate the severity of the illness:

P11: Cost versus potential outcome. If you are spending a thousand dollars testing for something,
which could have dire consequences for somebody, yes; maybe it’s worth it. If you are spending $10
on a test for a nosebleed or something, who cares?

Potential impact

[Second-level header]

a) Potential for benefit
Participants linked disease severity, potential life years gained and overall capacity to benefit. High
potential for benefit was constructed as worthy of funding, with the value of quality of life
improvements frequently given equal footing with extension of life.

P5: I put down quality of life. So is having the test and subsequently having the treatment, did that
prolong their life? Is it going to make their life better?
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Participants focused on capacity to benefit for specific subgroups, including vulnerable groups.
In doing so they drew on their understandings from interventions for seasonal influenza vaccination.
Participants rated access by high risk patient subgroups highly since those subgroups would benefit
most from testing thereby improving test accuracy or ‘hit rate’. Equity arguments per se were not used
to justify these choices.

P2: Depending on the disease, depending on who is more prevalent to actually get that type of
disease … Obviously you are going to want to have a hit rate that is going to be higher than just the
broad community. For example, the flu, they say they give it to the young, the elderly because they
are the ones that are going to be more affected by that particular type of thing.… You have to look at
the big picture of who would get the best benefit out of having the test.

In contrast, lifestyle choice, for example, the role of a vegan lifestyle in Vitamin B12 deficiency, even
though the individual may have high capacity to benefit, was constructed as a possible restrictive
condition on eligibility. Participants disagreed on this issue: some participants argued that restricting
funding in this way was discriminatory but there was little disagreement about the need to protect
those without choice. One participant summarised a stance that all supported:

P2: … this child is displaying those symptoms, being born by a vegan parent, to me that would be an
automatic inclusion. It’s something they haven’t chosen.

b) Cost to community of not testing
In addition to examining the individual test cost, attention was paid to the potential ongoing cost to the
community of doing nothing. Participants recognized that the cost of not doing a test could be
catastrophic for individuals and also very costly for society particularly in the long term. .

P8: … we thought it was important because it was investment in saving money down the track
possibly
[Two lines removed] P1: preventative rather than cure
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Community impact was directly linked to disease severity, with ongoing emotional and financial cost
for families highlighted, with one participant drawing on their understanding of the impact of spina
bifida:

P3: The example I was thinking of was spina bifida. The folate test, spina bifida could be prevented
apparently and if you have someone with spina bifida. It’s that person’s life ruined, and probably their
family, extended family. There’s cost of care, wheelchairs, ramps, ongoing medical; the cost never
ends, whereas the initial test would have hopefully prevented that.

The participants engaged with the potential for community impact broadly: for example, Vitamin B12
deficiency was seen as having less potential for community impact than folate deficiency and
therefore, as the following quote indicates, the imperative to fund the associated diagnostic test was
less.

P9: if you don’t have the [serum Vitamin B12] test and you aren’t treated for it, it still affects that
person in a negative way but not to the point that it is going to impact the community heavily.

c) Public Good
As shown above, public good was frequently prioritised over individual benefit in many of the
arguments raised by participants. Risk to others, particularly with respect to infectious disease
diagnosis, was seen as a special case because of potential impact on the broader community. This
criterion intersected with the criterion, cost of service, since participants saw the impact would be to
amplify overall cost:

P2: …if someone has an infectious disease and it's not brought to the attention of that person or
other professions, they are going into the community and they are going to infect so many more
people, then they are going to have to go through the same process with the same costings and that
costing gets blown out…
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Alternatives to testing

[Second-level header]

The participants all agreed that having ‘alternatives to testing’ was an important criterion. They
primarily focused on inexpensive non-invasive alternatives, including education and over-the-counter
medications. One forum member suggested preemptive treatment may be a solution:

P9: If you can identify suitably with a range of symptoms that you have a certain disease without the
test and you can try to treat it beforehand, I think, then performing the test itself is a waste of time and
money.

whereas another proposed more emphasis on prevention:

P8: …how many of us wear a hat when we go outside on a 30 degree day? How many of us wear
sunscreen and how much [sic] wear long sleeve tops when it’s hot? That is an alternative. Rather
than testing for skin cancer, the alternative was to provide communication, at a government level,
about slip, slop, slap. I would argue that actually may have been more effective than doing lots of skin
cancer tests.

Disease severity

[Second-level header]

The severity of the illness and therefore its potential community impact played a crucial role in
participants’ understandings of whether or not a test should be funded.

P3: It depends on the disease. If it’s flu, flu goes through the community. If it’s Ebola that is really
going to do harm, you have to be more aggressive.

Participants related degree of disease severity and seriousness of the treatment to test accuracy. The
extract below is an example of how participants reasoned that more burdensome diseases and
treatments might require greater test accuracy if they are to be funded.

P4: Just expanding on that, you would want to test if you are going to lose a kidney over it, you would
want it to be extremely accurate. While a test, say for [Vitamin] B12 really the treatment is not
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invasive, the treatment is not painful; we can afford a bit more of a gap in the accuracy because it’s
not going to harm the person…
[4 lines excluded]
P8: I think there should be minimum accuracy across the board…
[2 lines excluded]
P11: That makes sense. With the common diseases with no great consequence, your accuracy would
not have to be as great as for the more serious…

Accuracy

[Second-level header]

Accuracy (which might be more broadly construed as efficacy) was included as one of four primary
criteria to consider for disinvestment decisions but was rarely considered in isolation from the other
criteria. In the following extract accuracy was coupled with disease severity in deciding which of two
tests should be funded:

P1: I think for me, I’m thinking of a couple of examples where you can say there are two tests, one is
extremely accurate and expensive, one is less accurate and expensive, there may be some
circumstances where you want the less accurate one because you are saving resources, money.
[7 lines omitted]
P2: Depends on the consequences of the result. If you have got a disease that is far more serious,
you are going to want it to be as accurate as possible…

In general, less accurate tests were not considered financially ‘worthwhile’.

F: … What do we need to know to feel this is accurate enough that we are going to put money behind
it and fund it?
P5: It has to be worthwhile.
P4: It can’t be hit and miss.

Test accuracy was constructed both in terms of financial cost and health system impact but also
emotional toll on patients as this participant indicated:
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P4: Accuracy for the false positive, what would be the impact on this person once this test is run…
with the false positives? How angry would those people be…. and the financial implication of that.
F: We’ll break that down into the impact on the patient of those false positives.
P4: It’s not just the patient; it’s the impact on the health system.

Futility

[Second-level header]

Futility was not included in the list of criteria but some participants argued that, without appropriate
treatment, spending money on diagnostic tests was a waste of money and would adversely impact on
‘quality of life’ whereas others described the social value of a diagnosis. Interestingly several
participants saw a diagnosis without the possibility of treatment as a ‘personal choice’ and therefore
falling outside the scope of government funding as the following interchange demonstrates:
P6: … Why would you want to ruin your quality of life up to the point where you do die, knowing you
are going to die of something they can’t fix. You may as well die of something they can’t fix and enjoy
the time
P3: I would like to know
P6: I’m just putting it out there
F: At a policy level that is a question we have to ask. Are we happy to put money into something that
just does that; that just lets you know you have this amount of time before you die?
P8: We could spend that amount of money into research into it
P2: That is what I am saying, it’s a personal decision whether you want to have that defined answer
or not. Why would you want to fund that when that is a personal thing? If they want to know, that’s
fine, they can have the test…
P6: The question is whether you would subsidize that test
P2: Yeah, I don’t think you would subsidize something like that because I think that is a personal
choice
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Network of criteria

[Second-level header]

The participants did not treat their derived criteria as discrete entities. Rather, trade-offs were made
continuously, with participants’ reasoning forming a network of criteria which they used to justify
recommendations. The participants themselves were acutely aware of this: many participants
commented that the exercise was difficult because the criteria could not be considered in isolation
from one another:

P1: … these things are not stand alone. You would have to take them all together. If you found that a
test was very cheap but not very accurate, you’d have to weigh that against a test that was more
expensive but extremely accurate. You couldn’t just take one principle by itself; you had to look at all
those principles. We felt that whatever five priorities we picked up we couldn’t just go through a
standard single checklist for that particular item, there’d have to be a relationship between the two.

The nature of disinvestment

[Second-level header]

Beyond developing a set of criteria, participants also engaged with the nature of a potential
disinvestment process. Some participants questioned whether policy makers had “the authority” to
make these clinical decisions or whether the responsibility should lie with GPs either supported by “a
set guideline” or monitored through auditing. Others considered this meant the situation would not
change and the problem would continue. Tighter guidelines or descriptors for administering the test
were seen as potential ways of disinvesting, along with education and treatment strategies which
would avoid the need to test.
P8: …you would run through a checklist of things and not that you would ask every person in every
instance to go and do all those, go and take a vitamin supplement first. But it might narrow down and
it may determine – I don’t know if this is possible...
The ‘checklist’ for a test was seen as a way of supporting GPs to disinvest from relatively ineffective
technologies:
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P8: Having that checklist takes some of the pressure off the doctor who can say “look sorry, I can’t
write out that particular test for you because you haven’t met this criteria and that is the national
standard”.
Partial subsidies were proposed for tests which might be considered futile or where the condition
might be due to lifestyle factors. The following quote discusses a GP-patient encounter and a possible
response to a patient who might be B12 deficient because of dietary choices.
P8:If you have had six questions and they are questions about what types of food you eat things like
that, and the patient answers the question in such a way you go, “I’m not surprised” you might
consider if they get a full subsidy of the test or a partial subsidy.
Some participants considered that assessing individual tests in isolation was not the best approach
for containing health care costs.
P2: we have this big pool of money to cover all funding of all tests. … I’m saying we should be doing
[them] relative to each other. If we have a whole group of tests, if we try and bring our budget down,
have a group of tests that come under the same kind of classifications, what one should be saying, is
[one] more important than another.

Discussion [First-level Header]
Citizens engaged successfully in complex deliberation on a low profile technology, indicating that
deliberative engagement is possible for issues that may be seen as comparatively banal, as they sit
outside the big moral topics which normally form the basis of deliberative exercises (e.g. public
funding of genetic testing or nanotechnologies).(8)
Coherence between the findings of the forum and an expert-derived list of criteria described by
Elshaug et al. (28) is considerable, although the forum recommendations were presented using
different language and focus. The cost of service or test, potential impact in terms of likely health
impact, capacity to benefit and cost effects, cost-effective alternatives such as prevention and disease
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burden in terms of disease severity, all find their place in non-technical language within the
community forum’s criteria.

The major differences between the list generated by the citizens’ deliberative forum and the experts’
framework are shown in Table 1. In particular, the forum failed to consider equity whereas, unlike the
expert’s framework, they did consider ‘cost’ of social and emotional impact of disinvestment on users
and society. The absence of the latter in the experts’ framework could be seen as a major omission.
Reflecting their role as potential recipients of these services, the forum participants often put
themselves in the recipient’s position to justify chosen criteria. They also focused, however, on overall
community good and societal impact, sometimes at the expense of individual patient well-being, and,
perhaps as a consequence, they failed to incorporate considerations of equity into their
recommendations. The participants also indicated that they saw the criteria not as discrete entities,
but as an interconnected network. In particular, accuracy played a pivotal role for the participants in
understanding whether or not a test was worth funding, and other factors, such as cost and severity,
were reasoned in relation to test accuracy. This is not unreasonable since test accuracy is the first
line in evaluation of a diagnostic test: if a test is not accurate, testing cannot be efficacious.(29)

There are similarities between our study and a citizens’ jury (16) used to develop criteria applicable to
investment decision making for new health technologies in Canada. Despite examining quite different
technologies, using a more traditional jury format and looking at investment rather than disinvestment,
the criteria proposed in the Canadian citizens’ jury were similar to those described in our forum. There
were differences, however, in the level of priority accorded to the chosen criteria. In particular, the
Canadian jury prioritised first those technologies with potential to benefit many. This would equate to
our forum’s secondary criteria of potential for public good. Other prioritised criteria in both studies
included enhancement of quality of life (over extension of life span) and the lack of viable alternatives.
The Canadian jury concurred with the forum in this study, that future costs associated with not funding
a technology were important. They differed on the importance of technology unit cost – the Canadian
jury indicated this should never be a funding criterion whereas the Australian forum described this as
an essential item for consideration.
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Participants’ concerns about policy makers’ authority in disinvestment echo senior health policy
stakeholders’ own experience in negotiating “political sensitivities associated with…overt restrictions
on clinical autonomy and patient choice”.(20) The forum participants, in common with Australian
policy makers,(20) saw the need for coupling cost with quality of care in disinvestment decision
making. Given these shared concerns, attention to the use of language and reasoning by the forum
may help policy makers better engage in conversations about disinvestment in the broader
community.

Limitations [First-level Header]
Forum participants were not provided with information about the political barriers to disinvestment,
including falling community trust in government, nor were relevant ethical arguments brought to their
attention. This may have impacted on the nature of the recommendations and, in particular, their
inattention to equity issues. Thus, the deliberations cannot provide guidance to policy makers on how
to manage the political aspects of disinvestment which will be important to overcome the inertia
inherent in the system.(28) These issues were not discussed with the forum. In addition, the short
time for deliberation and the absence of a truly independent facilitator may have compromised the
ability of the participants to deliberate.(8) Although the final forum, fulfilled most of the recruitment
selection criteria, diversity in the forum may have been compromised by the high drop-out rate.(8)

Conclusions

[First-level Header]

Participants in this study identified issues important to citizens but neglected in the technology
assessment process including the societal impact of funding or not funding a technology and the
social and emotional fall-out from inaccuracy in a test reading. They also placed greater emphasis on
the importance of public good than on individual benefit.

Taxpayers are a significant force in the broader polity and, as such, their informed values, garnered in
considered deliberation, deserve respect as well as potentially providing a bulwark against vested
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interests of other stakeholders. This study demonstrates lay citizens can participate in deliberations
which form the basis of decision making for health technology assessment even where the
technologies have low public visibility. The ability of the forum participants to generate criteria that
have universal resonance supports the use of deliberative processes for the full range of health
technologies not only those which hold high public value and interest.
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Table 1. Criteria to inform the prioritisation of candidates for detailed review and potential
disinvestment
Expert criteria (Elshaug et al., 2009, (25))
Lay citizen criteria from jury
Cost of service: High cost per procedure (e.g.,
Cost of test (secondary): High cost per
high item cost of the Medicare Benefits Schedule procedure with little emphasis on cost by
or Pharmaceutical Benefits Scheme), high cost by volume although the overall cost was an
volume, or an aggregate of these.
impetus for action. The participants traded cost
per procedure against the cost of doing nothing,
the potential value associated with possible
outcomes, the availability of alternatives and the
potential for waste if the item were funded.

i.

ii.

iii.

Potential impact:
Likely health impact (e.g., crude estimate of
quality-adjusted life-years lost per patient).
Likely cost effects (e.g., crude estimate of
cost savings per patient; liberation of
additional resources, including downstream
costs such as theatre time required for
corrective procedures, and sunk costs of
human and physical capital, including costs
of retraining, and costs associated with
length of hospital stay).
Overall assessment relating to the
maintenance of equity in care should this
health care intervention be displaced (e.g.,
access by patient sub-groups).

18

Potential impact
i.
Potential to benefit (secondary)severity of health condition linked to
potential life years gained and potential
for improved quality of life and/or
extension of life. Possible exclusion
where the condition is related to
lifestyle choices.
ii.

Cost to community (not patients) of not
testing (primary) – financial cost to the
health system as well as ongoing
financial and emotional cost to
individuals and families.

iii.

Public good (secondary): in terms of
preventing contagious/infectious

disease and improving quality of life
Cost effective alternative: When a cheaper but
more, or equally, effective alternative exists, is
identified or emerges.
Disease burden: Conditions associated with low
degrees of disability or morbidity or low rates of
mortality (but excluding orphan conditions) may
influence priority differentially to those with high
degrees or rates. “Low” may reduce the potential
for controversy; “high” may represent greater
scope for reinvestment/reallocation of
resources.
Sufficient evidence available: Rigorous
assessment requires robust evidence on which
decisions can be made. While evidence is rarely
100% conclusive, it should be available and
adequate to offer decision-making utility.
Scope for time-limited funding with “pay for
evidence” or “only in research” provisions: If
there is not new, adequate or sufficient
evidence, but other criteria are met and/or there
is a moderate indication of (cost-)ineffectiveness
within existing evidence, then there should be
scope for “(time-limited) funding with evidence
generation” to assist decision-making.
Futility: An intervention that is highly unlikely to
result in “meaningful survival” or benefit. For
example, life-saving treatments for the seriously
demented (especially those who have given
advance directives); procedures that require
multiple stages to which patients have poor
adherence due to pain or side effects; and
treatments with high relapse rates.
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Alternatives (primary) : Including education,
prevention and alternative treatments
Severity (primary): with respect to both the
individual and the community

Accuracy (primary but always considered in
relation to other criteria) Accuracy is related to
severity of disease and relative to other tests

This area was not discussed by the forum

Futility – Although futility was not one of the
final criteria, some participants deemed as futile
testing where there was no potential for
effective treatment whereas others described
the value of a diagnosis.

